Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25887090 | 0.90 | ACHE (0.59) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23518844 | 0.89 | ACHE (0.55) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5244850 | 0.89 | ACHE (0.75) | ACHE | |
| SCHEMBL23945630 | 0.89 | ACHE (0.59) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5249534 | 0.88 | ACHE (0.50) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9773770 | 0.87 | ACHE (0.72) | ACHE | |
| SCHEMBL5700191 | 0.83 | ACHE (0.65) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12947556 | 0.82 | ACHE (0.55) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23806615 | 0.82 | CHRNB2 (0.55) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25143831 | 0.81 | ACHE (0.70) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ACHE 2778/4885CHRNB2 4503/4885CHRNB4 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.